Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,938.00GBp
12:07pm EDT
Change (% chg)

70.00 (+1.19%)
Prev Close
5,868.00
Open
5,899.00
Day's High
5,950.00
Day's Low
5,854.00
Volume
1,876,854
Avg. Vol
2,234,726
52-wk High
6,540.00
52-wk Low
5,110.00

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.88
Market Cap(Mil.): £77,101.38
Shares Outstanding(Mil.): 1,311.76
Dividend: 146.80
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 39.30 30.96 35.38
EPS (TTM): 1.50 -- --
ROI: 5.42 12.01 11.72
ROE: 20.58 13.30 16.38

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

May 08 2019

UPDATE 2-AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

* Plan to seek FDA approval in second half of year (Adds details on regulatory submission, analyst comment on potential sales)

May 08 2019

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

May 8 British drugmaker AstraZeneca and Japan's Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defences in a highly competitive oncology market.

May 08 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

May 02 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

May 2 British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

May 02 2019

UPDATE 3-European shares get a lift from strong earnings, U.S. GDP

April 26 European shares finished higher on Friday as some strong earnings and data showing U.S. economic growth in the first-quarter beat expectations helped cut losses from earlier in the session.

Apr 26 2019

Newer drugs fuel AstraZeneca quarterly sales beat

AstraZeneca Plc beat first-quarter sales and earnings expectations on Friday as the British drugmaker benefited from a push into cancer drugs and emerging markets including China.

Apr 26 2019

UPDATE 3-Newer drugs fuel AstraZeneca quarterly sales beat

* Current China growth rate not sustainable, still bullish (Adds executive comment, updates shares)

Apr 26 2019

UPDATE 1-UK Stocks-Factors to watch on April 26

April 26 Britain's FTSE 100 index is seen opening 4 points higher at 7,438 on Friday, according to financial bookmakers, while FTSE 100 futures were up 0.07 percent ahead of the cash market open.

Apr 26 2019

AstraZeneca first-quarter product sales beat estimates

April 26 British drugmaker AstraZeneca Plc's first-quarter product sales beat analysts' expectations on Friday, benefiting from higher demand for its cancer medicines.

Apr 26 2019

Earnings vs. Estimates